Jacobs Levy Equity Management
BIVV

Jacobs Levy Equity Management’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Jacobs Levy Equity Management’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-121,463
Closed -$6.93M – 1122
2017
Q3 		$6.93M Buy
+121,463
New +$7.11M 0.13% 211

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Jacobs Levy Equity Management's BIVV Position: Q4 2017 in Review

Jacobs Levy Equity Management sold out of Bioverativ Inc. Common Stock (BIVV) in Q4 2017, closing a stake of 121,463 shares — an estimated $6.93M sold.

Jacobs Levy Equity Management first reported a position in BIVV in Q3 2017 and held it in 1 quarter. The position peaked at $6.93M in Q3 2017. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Jacobs Levy Equity Management reported no remaining Bioverativ Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 121,463 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $6.93M.
  • Jacobs Levy Equity Management first reported a position in Bioverativ Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Bioverativ Inc. Common Stock position peaked at $6.93M in Q3 2017.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2017, filed 13 Feb 2018.